To the Editor:

Several countries have applied exemptions of respiratory patients on the compulsory use of face masks indoors and outdoors during the coronavirus disease 2019 (COVID-19) pandemic. It must be strongly stated that such exemption is not evidence-based, and it may carry increased risk of personal infection to the estimated 544.9 million people worldwide suffering a chronic respiratory disease [1].

Beyond hand hygiene and physical distancing, face masks are fundamental for personal and group protection to prevent the spread of infection both in patients and in their caretakers [2].

Ultimately, human behaviour is certainly the main determinant of the spread or containment of the disease. Considering that the virus spreads largely through the respiratory tract, experts are proposing that beyond protecting others, face masks help their wearers. In the new (although not fully demonstrated) COVID-19 inoculum theory, it is proposed that universal masking reduces the inoculum or dose of the virus for the wearer, leading to milder or asymptomatic infection [3, 4].

Many countries have already defined national policies to implement compulsory use of face masks (figure 1) [5]. Further, several countries have instituted penalties for non-compliant individuals. But there are exceptions. In Spain, since 21 May, 2020 [6], face masks must be worn in the “public street, in open-air spaces and any closed space that is for public use or that is open to the public, where it is not possible to maintain [an interpersonal] distance of two meters”. According to the Spanish order, “people with respiratory problems, or those who cannot wear masks for other health reasons or due to a disability, are exempt from wearing them”. In the USA, certain “Face Mask Exemption Cards” are already circulating [7].

At this stage, it is important to address the question: Are there medically justified exemptions for face coverings?

Relieving respiratory patients from the obligation to wear masks could be highly deleterious for them, since by definition those patients with respiratory conditions who cannot tolerate face masks are at higher risk of severe COVID-19.

Although facemasks undoubtedly enhance breathing resistances, the degree of discomfort experienced by some patients is influenced by its affective component.

Dyspnoea is a sensation, and supratentorial affects such as anxiety and claustrophobia might cause the added sensation of “being unable to breathe” with a mask. Indeed, the World Health Organization states that face masks of breathable material, worn properly, will not lead to health problems.

Whether persons not wearing facemasks play a role in the persistence or resurgence of COVID-19 in many countries is not firmly established. We must acknowledge that there is not a body of evidence (yet) to support the proposed approach of universally recommending facemasks in public. Any statement suggesting that all types of face masks have a protective role, needs to be accompanied by the underpinning need to differentiate their diversity.

Similar to “drugs”, the efficacy of face masks depends highly on a number of characteristics, some of which have been formally assessed and some which have not or cannot easily (e.g. comfort, social acceptance). The second waves being experienced globally, despite widespread masking, confirm masks are insufficient interventions. With all likelihood, it is about a large number of issues, not just masks.

At this time, professional associations have not provided clear recommendations on exemptions (or lack thereof). Within the Respiratory Effectiveness Group, we do not see asthma, COPD and other respiratory diseases as an impediment to wear a face mask, unless the person is in acute respiratory distress, in which case going out in public is not advised. Therefore, we propose the cautionary step not to exempt respiratory patients from the compulsory use of face masks.

Our duty remains to encourage patients to follow strictly the measures aiming at protecting them from getting or transmitting the disease. Adaptations of their activities (less time spent in public spaces) may be required to decrease the time during which they need to wear a face mask, and whenever possible other protective measures could be utilised (e.g. social distancing).

COVID-19 is a new, devastating, but potentially preventable disease, and a key priority is to identify the combination of measures that minimises societal and economic disruption while adequately controlling infection [8]. It is crucial for patients with respiratory conditions to wear face masks when they are in public spaces where social distancing cannot be applied easily [9]. Developing new models of face masks dedicated at patients with impaired lung function could be of help.

Joan B. Soriano 1,2, Antonio Anzueto 3,4, Sinthia Bosnic Anticevich 5, Alan Kaplan 6, Marc Miravitlles 6,7, Omar Usmani 8, Nikolaos G. Papadopoulos 9,10, Francesca Puggioni 11,12, G. Walter Canonica 11,12 and Nicolas Roche 13, on behalf of the Respiratory Effectiveness Group

1Servicio de Neumología, Hospital Universitario La Princesa, Madrid, Spain. 2Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. 3Division of Pulmonary Diseases and Critical Care Medicine, The University of Texas Health, San Antonio, TX, USA. 4Pulmonary Diseases Section, Audie L. Murphy Memorial VA Hospital, South Texas Veterans Health Care System, San Antonio, TX, USA. 5Woolcock Institute of Medical Research, The University of Sydney, Sydney Local Health District, Sydney, Australia. 6Dept of Family and Community Medicine, University of Toronto, Toronto, ON, Canada. 7Pneumology Dept, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain. 8National Heart and Lung Institute, Imperial College London and Royal Brompton Hospital, Airways Disease Section, London, UK. 9Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK. 10Allergy Dept, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece. 11Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center, IRCSS, Rozzano, Italy. 12Dept of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy. 13Respiratory Medicine, Hôpital Cochin, APHP Centre, Université de Paris (UMR1016, Institut Cochin), Paris, France.

Correspondence: Joan B. Soriano, Servicio de Neumología, Hospital Universitario La Princesa, Madrid, Spain.
E-mail: jsoriano2@gmail.com

Received: 7 Aug 2020 | Accepted after revision: 7 Sept 2020

Author contributions: J.B. Soriano conceived the manuscript. All authors contributed to several drafts and approved its final version.
Conflict of interest: J.B. Soriano has nothing to disclose. A. Anzueto reports personal fees for consultancy from GlaxoSmithKline, Boehringer Ingelheim and AstraZeneca, outside the submitted work. S. Bosnic Anticevich reports grants and personal fees for lectures and advisory board work from Teva, personal fees for lectures and advisory board work from AstraZeneca, personal fees for lectures and advisory board work from Boehringer Ingelheim, personal fees for lectures from GSK, personal fees for consultancy from Sanofi and Mylan, outside the submitted work. A. Kaplan has nothing to disclose. M. Miravitlles reports personal fees for lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Zambon, Sandoz, CSL Behring, Grifols and Novartis, personal fees for consultancy from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratories Esteve, Ferrer, Mereo Biopharma, Verona Pharma, Kamada, TEVA, Sanofi, pH Pharma, Novartis and Grifols, grants from GlaxoSmithKline and Grifols, outside the submitted work. O. Usmani has nothing to disclose. N.G. Papadopoulos has nothing to disclose. F. Puggioni reports personal fees from Sanofi, Novartis, GlaxoSmithKline, AstraZeneca, Chiesi, Menarini, Mundipharma, Boehringer, Valeas, Aik Abello and Allergy Therapeutics, outside the submitted work. G.W. Canonica has nothing to disclose. N. Roche has nothing to disclose.

References